Cell Therapy News Volume 26.00 | Jan 13 2025

    0
    40







    2025-01-13 | CTN 26.00


    Cell Therapy News by STEMCELL Technologies
    Vol. 26.00 – 13 January, 2025
    TOP STORY

    T Cell Malignancies after CAR T Cell Therapy in the DESCAR-T Registry

    The authors analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018.
    [Nature Medicine]

    Abstract
    PUBLICATIONSListed by the impact factor of the journal

    Autologous Macrophage Therapy for Liver Cirrhosis: A Phase II Open-Label Randomized Controlled Trial

    Scientists evaluated the efficacy of autologous monocyte-derived macrophage therapy compared to standard medical care in adult patients with compensated cirrhosis and Model for End-Stage Liver Disease.
    [Nature Medicine]

    Full Article

    Defining Ortholog-Specific UHRF1 Inhibition by STELLA for Cancer Therapy

    Investigators demonstrated that human STELLA was inadequate, while mouse STELLA was fully proficient in inhibiting the abnormal DNA methylation and oncogenic functions of ubiquitin-like with plant homeodomain and RING finger domains 1 (UHRF1) in human cancer cells.
    [Nature Communications]

    Full Article

    Dual-Targeting CRISPR-CasRx Reduces C9orf72 ALS/FTD Sense and Antisense Repeat RNAs In Vitro and In Vivo

    The authors showed CRISPR-Cas13d variant CasRx effectively reduced overexpressed C9orf72 sense and antisense repeat transcripts and dipeptide repeat proteins in HEK cells.
    [Nature Communications]

    Full Article

    A First-in-Human Clinical Study of an Allogenic iPSC-Derived Corneal Endothelial Cell Substitute Transplantation for Bullous Keratopathy

    A first-in-human clinical study of a corneal endothelial cell substitute derived from a clinical-grade iPSC line showed improvement of visual acuity and corneal stromal edema, with no adverse events for up to one year after surgery for the treatment of bullous keratopathy.
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract

    The High Efficacy of claudin18.2-Targeted CAR-T Cell Therapy in Advanced Pancreatic Cancer with a Strategy to Ensure the Safety of Patients

    Scientists reported the utilization of tEGFR-expressing claudin18.2-targeted CAR-T cells to treat three patients with advanced pancreatic cancer.
    [Molecular Therapy]

    AbstractGraphical Abstract

    XCL1-Secreting CEA CAR T Cells Enhance Endogenous CD8+ T Cell Responses to Tumor Neoantigens to Confer a Long-Term Antitumor Immunity

    Researchers modified carcinoembryonic antigen (CEA)-specific CAR-T cells, aiming to stimulate endogenous CD8+ T cell responses against neoantigens that were derived from CEA-positive tumors destroyed by the CAR T cells.
    [Journal For Immunotherapy of Cancer]

    Full Article

    Gene Editing Enables Non-Invasive In Vivo PET Imaging of Human Induced Pluripotent Stem Cell Derived Liver Bud Organoids

    The authors gene-edited a cGMP compliant human induced pluripotent stem cell (hiPSC) line at the AAVS1 safe harbor locus enabling constitutive expression of a human sodium iodide symporter-monomeric(m)GFP fusion reporter in hiPSCs and their differentiated progeny.
    [Molecular Therapy-Methods & Clinical Development]

    AbstractFull ArticleGraphical Abstract

    Identifying Novel Response Markers for Spinal Muscular Atrophy Revealed by Targeted Proteomics following Gene Therapy

    Researchers chose the novel nucleic acid linked immuno-sandwich assay, to investigate a predefined panel of neuroinflammatory markers in plasma samples collected from spinal muscular atrophy patients at baseline and six months after Zolgensma® treatment.
    [Gene Therapy]

    Abstract
    REVIEWS

    Recent Developments in Myeloid Immune Modulation in Cancer Therapy

    Investigators discuss recent approaches to clinically target tumor myeloid cells, focusing on reprogramming myeloid cells to promote antitumor immunity.
    [Trends in Cancer]

    Abstract
    INDUSTRY AND POLICY NEWS

    RNA Gene Therapies Offer Hope for Millions with High Cholesterol

    Base editing, antisense oligonucleotides, and siRNA therapies that target low-density lipoprotein and the genes encoding molecules that regulate it are being tested in several clinical trials.
    [Nature Medicine]

    News Article

    BlueRock Therapeutics Advances Investigational Cell Therapy Bemdaneprocel for Treating Parkinson’s Disease to Registrational Phase III Clinical Trial

    Bayer AG and BlueRock Therapeutics LP announced plans to initiate a Phase III clinical trial for bemdaneprocel, its investigational cell therapy for Parkinson’s disease.
    [BlueRock Therapeutics]

    Press Release
    FEATURED EVENT

    DNA Methylation, Clonal Hematopoiesis, and Cancer

    February 1-4, 2025
    San Diego, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Co-op – Gene Therapy Immunogenicity

    Biogen – Cambridge, Massachusetts, United States

    Faculty – Stem Cell and Gene Therapy

    University of California San Francisco – San Francisco, California, United States

    Principal Scientist – Experimental Immunology

    Biogen – San Francisco, California, United States

    Tenure-Track Junior PI – Cancer Immunity and Immunotherapy Research

    IFOM ETS – The AIRC Institute of Molecular Oncology – Milan, Italy

    Postdoctoral Scientist – Cancer Biology

    The University of Pennsylvania – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2